Skip to main content

Table 1 Main characteristics of the eligible studies

From: Prognostic value of lymph node ratio in laryngeal and hypopharyngeal squamous cell carcinoma: a systematic review and meta-analysis

StudyYearRegionStudy periodType of studyPopulationEndpoints with HRLNR cut-offMethod of LNR determinationFollow-up time (months)
Ye [22]2018China2007 to 2016retrospectiveHPSCCOS, DFS<0.07,≥0.07ROCMedian 33.1
(6.1 to 110.7)
Lo [15]2017Taipei, China2001 to 2007retrospectiveHPSCCOS, DFS, DSS< 0.113, ≥0.113MeanMean 51
(4 to 144)
Suzuki [21]2016Japan2000 to 2015prospectiveHPSCCOS, DFS< 0.09, ≥0.09Log-rank testMean ± SD
45.7 ± 40.6
Joo [14]2015Korea1993 to 2014retrospectiveHPSCCOS, DFS< 0.055, ≥0.055ROCMean 37
(1 to 151)
Hua [13]2015China2000 to 2005retrospectiveHPSCCOS< 10, > 10%NAMedian 48
(12 to 127)
Yu [29]2013China1965 to 2008retrospectiveHPSCCOS, DFS, DSS≤0.14, > 0.14LNR quartilesMean 41.8
(1 to 295)
Wang [27]2013SEER1988 to 2008retrospectiveHPSCCOS, DFS0–0.05, 0.05–0.30, > 0.30Log-rank testMedian 23
(0 to 238)
Imre [19]2016Turkey2006 to 2014retrospectiveLSCCOS, DFS< 0.09, ≥0.09Univariate Cox analysisMean 33.5
(6 to 94)
Ryu [16]2015Korea2001 to 2010retrospectiveLSCCDFS≤0.044, > 0.044ROCMedian 53.2
(2.1 to 147.1)
Wang [28]2014SEER1988 to 2008retrospectiveLSCCOS, DFS0–0.09, 0.09–0.20, > 0.20Log-rank testNA
Künzel [20]2015Germany1980 to 2010retrospectiveLSCCDFS< 0.09, > 0.09/< 0.09, > 0.09ROCMean 53
(0.1 to 229)
Choi [12]2019Germany2006 to 2016retrospectiveHPSCC/LSCCOS, DFS, DSS0.03ROCMedian 60
(24 to 134)
Grasl [18]2019Austria1994 to 2018retrospectiveHPSCC/LSCCOS, DFS, DSS≤0.07, > 0.07ROCMean ± SD
55.6 ± 59.3
  1. HPSCC hypopharyngeal squamous cell carcinoma, LSCC laryngeal squamous cell carcinoma, OS overall survival, DSS disease-specific survival, DFS disease-free survival, ROC receiver operating characteristic; NA: not available